Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.
about
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI InhibitorsAxitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformationAxitinib Improves Radiotherapy in Murine Xenograft Lung Tumors.A streamlined search technology for identification of synergistic drug combinations.Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.Axitinib in metastatic renal cell carcinoma: single center experience.Thyroid dysfunctions induced by tyrosine kinase inhibitors.Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.Axitinib plasma pharmacokinetics and ethnic differences.A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.Tivozanib: status of development.The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibitionThe FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma.
P2860
Q26764892-5CCAC4A1-44CB-4291-B7EB-D53831629AF2Q27698001-E7BFEC74-FA08-4715-B130-21926C4640EBQ34092023-012928B7-0CA8-4DBB-98E7-6756B1AF57BCQ36101810-751F6557-D747-427E-9D09-BD81D7E6940BQ36918281-F5E91370-64AD-445D-B0FA-E5CDB31421CFQ37657679-E145637D-97F2-4341-A3BF-C0112FF094E3Q38211342-524F7AD5-CF69-4923-83A1-7D66B3A693C3Q38261099-B1A6723C-AB15-41FA-8B43-81353E075999Q38348548-622B37E5-9733-442E-813B-D32D42CE4237Q38378485-F6637BC9-73BD-4D13-B1E1-87AAE1B6996DQ38431182-323E2802-6277-4E16-90B9-55AB3ADAC62BQ41470815-6E374253-9C11-408F-9776-DD2C7EBC36FDQ48150834-BB6A8944-E6AD-41CA-8D39-4E2B0115A029Q52922028-286B091E-996B-4456-9AE7-9EF039EA1BDA
P2860
Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Axitinib: a review of its safe ...... advanced renal cell carcinoma.
@en
type
label
Axitinib: a review of its safe ...... advanced renal cell carcinoma.
@en
prefLabel
Axitinib: a review of its safe ...... advanced renal cell carcinoma.
@en
P2093
P2860
P356
P1476
Axitinib: a review of its safe ...... advanced renal cell carcinoma
@en
P2093
Amandine Quivy
Louis François
Marine Gross-Goupil
P2860
P304
P356
10.4137/CMO.S10594
P407
P50
P577
2013-10-29T00:00:00Z